Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures: 2016-2025

Historic Gains from Sales and Divestitures for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $980,992.

  • Collegium Pharmaceutical's Gains from Sales and Divestitures rose 4.32% to $980,992 in Q3 2025 from the same period last year, while for Sep 2025 it was $980,992, marking a year-over-year increase of 4.32%. This contributed to the annual value of $967,773 for FY2024, which is 43.24% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Gains from Sales and Divestitures is $980,992, which was up 9.52% from $895,705 recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Gains from Sales and Divestitures registered a high of $980,992 during Q3 2025, and its lowest value of $352,548 during Q1 2021.
  • Its 3-year average for Gains from Sales and Divestitures is $785,576, with a median of $792,945 in 2025.
  • Data for Collegium Pharmaceutical's Gains from Sales and Divestitures shows a peak YoY spiked of 80.53% (in 2021) over the last 5 years.
  • Collegium Pharmaceutical's Gains from Sales and Divestitures (Quarterly) stood at $444,769 in 2021, then grew by 28.88% to $573,204 in 2022, then grew by 17.87% to $675,647 in 2023, then skyrocketed by 43.24% to $967,773 in 2024, then increased by 4.32% to $980,992 in 2025.
  • Its Gains from Sales and Divestitures was $980,992 in Q3 2025, compared to $895,705 in Q2 2025 and $792,945 in Q1 2025.